Mabwell(SH:688062) Xin Lang Cai Jing·2025-11-07 01:40Group 1 - The core viewpoint of the news is that Maiwei Biotech has shown significant financial activity, with a notable increase in revenue and changes in shareholder structure [1][2]. Group 2 - As of November 6, 2023, Maiwei Biotech's stock price increased by 0.50%, with a trading volume of 304 million yuan. The financing buy-in amount was 22.19 million yuan, while the financing repayment was 30.38 million yuan, resulting in a net financing buy of -8.19 million yuan [1]. - The total margin balance for Maiwei Biotech reached 613 million yuan, with the financing balance accounting for 6.74% of the circulating market value, indicating a high level compared to the past year [1]. - The company has not engaged in any short selling on November 6, 2023, with a short selling balance of 93.38 million yuan, also reflecting a high level compared to the past year [1]. Group 3 - For the period from January to September 2025, Maiwei Biotech reported a revenue of 566 million yuan, representing a year-on-year growth of 301.03%. However, the net profit attributable to the parent company was -598 million yuan, showing a year-on-year increase of 13.89% [2]. - As of September 30, 2025, the number of shareholders for Maiwei Biotech reached 19,600, an increase of 9.15% from the previous period. The average circulating shares per person decreased by 8.38% to 10,425 shares [2]. - Among the top ten circulating shareholders, E Fund Medical Healthcare Industry Mixed A ranked as the fourth largest shareholder with 3.17 million shares, while Hong Kong Central Clearing Limited ranked sixth with 2.87 million shares, showing a decrease of 1.87 million shares from the previous period [2].